EAST TAUNTON, Mass.--(BUSINESS WIRE)--OMNIlife science, Inc. ("OMNI"), an established medical technology company targeting the $15 billion and rapidly growing global hip and knee replacement medical device sector, has appointed Christian Joly as its Vice President of Robotics and Navigation, effective immediately. In this role, he will oversee OMNI’s robotic navigation and commercialization strategies, direct the core robotic navigation business, help develop new go-to-market strategies and set the strategic direction for OMNI’s capital products business.
Mr. Joly brings more than 25 years of executive experience running international companies that specialized in technology, including medical imaging and data processing. Most recently, he served as the CEO of AdRoxx, a SaaS company focused on big data related to geotargeted information. Prior to AdRoxx, he was the Chairman and CEO of Praxim, a medical device company that was acquired by OMNI’s parent company in June 2010. Before Praxim, Mr. Joly was the CEO of TAK Imaging, which was acquired by InSilica. Prior to TAK Imaging, he was Senior Vice President of Marketing and Business Development at Intellon Corporation, where he was critical to steering the company on a growth path by focusing on tactical sales and developing strategic relationships with video-based customers. Prior to Intellon, he headed the DVD and Imaging Business Units at LSI LOGIC. He holds an EDP in general management from the Kellogg School of General Management at Northwestern University and a B.S. in electrical engineering from the University of Rennes, France. In addition to his experience in leadership roles, he has been granted seven patents in the areas of VLSI design and imaging.
Mr. Joly said, “There is a significant need for innovation in the hip and knee surgical arena, and OMNI is on the cutting edge of work in this space. I am pleased to be able to leverage my years of experience in the medical technology sector to continue the pace and quality of work that is being done by the company. The advanced robotic plans we have with OMNIlife science are not only exciting but revolutionary. I look forward to working with the rest of the management team in the months and years ahead, as we enhance the products and technology we offer to surgeons.”
George B. Cipolletti, President and CEO of OMNI, commented, “Christian Joly brings a tremendous amount of industry experience to our company, and we are honored to have him serve as our Vice President, Robotics and Navigation. In this role, he will report directly to me and work closely with the rest of the management team. We are confident his expertise will help propel OMNIlife science forward to its next stage of growth and success.”
About OMNIlife science, Inc.
OMNI is an established hip and knee implant replacement engineering, manufacturing and distribution company that has also developed a proprietary Robotics and Navigation platform, called OMNInavTM, that uses proprietary computer assisted robotic cutting guide technology, or "OMNIplastyTM".
Statements in this press release concerning the future business, operations and prospects of OMNIlife science, Inc., including its advance robotic plans and the effect of hiring Mr. Joly, as well as statements using the terms “plans,” “confident” or similar expressions are “forward looking” statements as defined in the Private Securities Litigation Reform Act of 1995. These statements are based upon management's current expectations and are subject to a number of factors and uncertainties. Information contained in these forward looking statements is inherently uncertain, and actual performance and results may differ materially due to many important factors. Such factors include, among others, changes in competitive conditions and pricing in OMNI’s markets, decrease in the demand for OMNI’s products, delays in OMNI’s product research and development cycles, decreases in the use of OMNI’s principal product lines or in procedure volume, unanticipated issues in complying with domestic or foreign regulatory requirements related to OMNI’s current products or securing regulatory clearance or approvals for new products or upgrades or changes to OMNI’s current products, the impact of the United States healthcare reform legislation on hospital spending and reimbursement, any unanticipated impact arising out of the securities class action or any other litigation, inquiry, or investigation brought against OMNI, increases in costs of OMNI’s sales force and distributors, and unanticipated intellectual property expenditures required to develop, market, and defend OMNI’s products. OMNI cannot guarantee any future results, levels of activity, performance or achievement. OMNI undertakes no obligation to update any of its forward looking statements after the date of this press release.